Olaparib is a prescription medicine used to treat advanced Ovarian cancer, It is for patients whose cancerhas certain mutations in the BRCA1 and BRCA2 genes and who have already been treated with at least three other types of chemotherapy.Olaparib is also being studied in the treatment of other types of cancer.
Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.
Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug.
